Aurinia Pharmaceuticals
AUPH
171 hedge funds and large institutions have $320M invested in Aurinia Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 47 reducing their positions, and 31 closing their positions.
47% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $6.94M
21% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 47
14% more capital invested
Capital invested by funds: $281M → $320M (+$38.8M)
0.57% more ownership
Funds ownership: 38.61% → 39.18% (+0.57%)
4% less funds holding
Funds holding: 179 → 171 (-8)
19% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.84M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.53M |
| 3 |
BlackRock
New York
|
+$3.21M |
| 4 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$2.92M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.92M |
| 2 |
LFAS
Level Four Advisory Services
Dallas,
Texas
|
-$2.13M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$1.99M |
| 4 |
Morgan Stanley
New York
|
-$1.67M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.45M |
AUPH Hedge Fund Activity: Q2 2024 in Review
171 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2024, worth a combined $320M — up 14% from $281M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of AUPH and 25 opened new positions — a net loss of 6 holders — while 47 trimmed existing stakes and 57 added.
The largest buyer was Tang Capital Management, adding an estimated $3.84M. The largest seller was Armistice Capital, cutting an estimated $5.92M.
- 171 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2024, down from 179 in Q1 2024.
- Funds reported $320M of Aurinia Pharmaceuticals stock for Q2 2024, up 14% quarter-over-quarter.
- 25 funds opened new Aurinia Pharmaceuticals positions in Q2 2024 and 31 closed out, a net change of -6 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2024 was Tang Capital Management, an estimated $3.84M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2024 was Armistice Capital, an estimated $5.92M sold.
Based on aggregated 13F filings for Q2 2024.